Trade BCTXZ stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
BriaCell Therapeutics Corp. Warrant expiring 2030 (BCTXZ) is trading at US$0.17, down 15.30% today as of Oct 14, 16:00 EDT. Over the past 52 weeks, BCTXZ has traded between US$0.06 and US$0.48. On Syfe you can trade BCTXZ with $0 commission and add it to your watchlist.
| Previous close | US$0.20 |
|---|---|
| 52-week range | US$0.06 – US$0.48 |
| Volume | 17.11K |
| Exchange | US |
BriaCell Therapeutics Corp. Warrant expiring 2030
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. It currently advancing its Bria-IMT™ targeted immunotherapy in combination with an immune check point inhibitor in a pivotal 1 Phase 3 study in metastatic breast cancer. The company was founded by Charles L. Wiseman and Isaac Benjamin Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.
Year: 2025
BriaCell Therapeutics Corp. Warrant expiring 2030 (BCTXZ) stock is trading at US$0.17, -15.30% from the previous close of US$0.20.
The 52-week high for BriaCell Therapeutics Corp. Warrant expiring 2030 (BCTXZ) stock is US$0.48.
The 52-week low for BriaCell Therapeutics Corp. Warrant expiring 2030 (BCTXZ) stock is US$0.06.
BriaCell Therapeutics Corp. Warrant expiring 2030 (BCTXZ) does not currently pay a dividend.
Stay on top of BCTXZ
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
Popular Stocks in Singapore
